Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Category: Claim Construction
-
Since it has been a while since my last post, I’m going to do something a little different and do a quick run down of ten Federal Circuit cases that have issued in the past few months and highlight some key takeaways. I’ll give a quick bullet point review of the cases, with slightly more…
-
In a recently unsealed opinion, a N.D.W.V. court denied Regeneron's motion for a preliminary injunction against Amgen seeking to enjoin Amgen's ABP 938, a biosimilar version of Eylea. Regeneron had previously been successful in obtaining preliminary injunctions in the same court against a number of other defendants. But Amgen's formulation differed from those defendants, resulting…
Orange Book Blog 